JP2014028857A - Chlorous acid compound-containing aqueous composition containing menthol - Google Patents
Chlorous acid compound-containing aqueous composition containing menthol Download PDFInfo
- Publication number
- JP2014028857A JP2014028857A JP2013223062A JP2013223062A JP2014028857A JP 2014028857 A JP2014028857 A JP 2014028857A JP 2013223062 A JP2013223062 A JP 2013223062A JP 2013223062 A JP2013223062 A JP 2013223062A JP 2014028857 A JP2014028857 A JP 2014028857A
- Authority
- JP
- Japan
- Prior art keywords
- aqueous composition
- contact lens
- solution
- chlorous acid
- contact lenses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 149
- 229940077239 chlorous acid Drugs 0.000 title claims abstract description 27
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229940041616 menthol Drugs 0.000 title claims abstract description 24
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 title claims abstract 6
- -1 Chlorous acid compound Chemical class 0.000 title abstract description 57
- 239000000243 solution Substances 0.000 claims abstract description 47
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 33
- 239000003889 eye drop Substances 0.000 claims abstract description 29
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 11
- 206010013774 Dry eye Diseases 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims description 34
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims description 30
- 230000001954 sterilising effect Effects 0.000 claims description 22
- 229910001919 chlorite Inorganic materials 0.000 claims description 18
- 229910052619 chlorite group Inorganic materials 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 238000004140 cleaning Methods 0.000 claims description 14
- 239000003755 preservative agent Substances 0.000 claims description 11
- 230000000249 desinfective effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 5
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 claims description 5
- 229960002218 sodium chlorite Drugs 0.000 claims description 5
- 239000012487 rinsing solution Substances 0.000 claims description 4
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 claims description 3
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 19
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract description 19
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 abstract description 19
- 241000723346 Cinnamomum camphora Species 0.000 abstract description 19
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract description 19
- 229940116229 borneol Drugs 0.000 abstract description 19
- 229930008380 camphor Natural products 0.000 abstract description 19
- 229960000846 camphor Drugs 0.000 abstract description 19
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract description 19
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 abstract description 18
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 abstract description 18
- 229930007503 menthone Natural products 0.000 abstract description 18
- 239000007788 liquid Substances 0.000 abstract description 6
- 230000002421 anti-septic effect Effects 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 20
- 229940012356 eye drops Drugs 0.000 description 16
- 238000004659 sterilization and disinfection Methods 0.000 description 16
- 244000005700 microbiome Species 0.000 description 14
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000645 desinfectant Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 229960000686 benzalkonium chloride Drugs 0.000 description 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 8
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 7
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 7
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 231100000040 eye damage Toxicity 0.000 description 6
- 239000007951 isotonicity adjuster Substances 0.000 description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 6
- 229960002216 methylparaben Drugs 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000003002 pH adjusting agent Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000004155 Chlorine dioxide Substances 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019398 chlorine dioxide Nutrition 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 229940068988 potassium aspartate Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000015227 regulation of liquid surface tension Effects 0.000 description 3
- 229940083542 sodium Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- QAQSNXHKHKONNS-UHFFFAOYSA-N 1-ethyl-2-hydroxy-4-methyl-6-oxopyridine-3-carboxamide Chemical compound CCN1C(O)=C(C(N)=O)C(C)=CC1=O QAQSNXHKHKONNS-UHFFFAOYSA-N 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 241000224422 Acanthamoeba Species 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000607715 Serratia marcescens Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical class OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 2
- 229940048820 edetates Drugs 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011086 high cleaning Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 229960001983 magnesium aspartate Drugs 0.000 description 2
- CRSJYWPXKKSOCQ-CBAPHJFVSA-L magnesium;(2s)-2-aminobutanedioate;hydron;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O CRSJYWPXKKSOCQ-CBAPHJFVSA-L 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229940044476 poloxamer 407 Drugs 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- NYEPHMYJRNWPLA-UHFFFAOYSA-N (6-amino-2-ethoxyacridin-9-yl)azanium;2-hydroxypropanoate;hydrate Chemical compound O.CC(O)C([O-])=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3[NH+]=C21 NYEPHMYJRNWPLA-UHFFFAOYSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 208000034006 Device colour issue Diseases 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- XLRHXNIVIZZOON-WFUPGROFSA-L Flavin adenine dinucleotide disodium Chemical compound [Na+].[Na+].C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 XLRHXNIVIZZOON-WFUPGROFSA-L 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 1
- GWVPJQDUGPKIOI-UQKRIMTDSA-N [Na].CCCCCCCCCCCC(=O)CN[C@@H](C)C(O)=O Chemical compound [Na].CCCCCCCCCCCC(=O)CN[C@@H](C)C(O)=O GWVPJQDUGPKIOI-UQKRIMTDSA-N 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 1
- 229960003731 amlexanox Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- FYBWCLKVKGHJKS-UHFFFAOYSA-L berberine sesquihydrate sulfate Chemical compound O.O.O.[O-]S([O-])(=O)=O.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2.C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 FYBWCLKVKGHJKS-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-M chlorate Inorganic materials [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- MAYPHUUCLRDEAZ-UHFFFAOYSA-N chlorine peroxide Chemical compound ClOOCl MAYPHUUCLRDEAZ-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 229910001907 dichlorine dioxide Inorganic materials 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000010643 fennel seed oil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- NFFJLMKHRCXLJO-DKWTVANSSA-L magnesium;(2s)-2-aminobutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O NFFJLMKHRCXLJO-DKWTVANSSA-L 0.000 description 1
- YZQBYALVHAANGI-UHFFFAOYSA-N magnesium;dihypochlorite Chemical compound [Mg+2].Cl[O-].Cl[O-] YZQBYALVHAANGI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 1
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229960004811 pemirolast potassium Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- SATVIFGJTRRDQU-UHFFFAOYSA-N potassium hypochlorite Chemical compound [K+].Cl[O-] SATVIFGJTRRDQU-UHFFFAOYSA-N 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 1
- JVUYWILPYBCNNG-UHFFFAOYSA-N potassium;oxido(oxo)borane Chemical compound [K+].[O-]B=O JVUYWILPYBCNNG-UHFFFAOYSA-N 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 description 1
- RUTSRVMUIGMTHJ-UHFFFAOYSA-M sodium;tetradec-1-ene-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCC=CS([O-])(=O)=O RUTSRVMUIGMTHJ-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 229960001975 sulfisomidine Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- XFHHCPRMDXAWDO-UHFFFAOYSA-K trisodium;1-dodecoxydodecane;phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.CCCCCCCCCCCCOCCCCCCCCCCCC XFHHCPRMDXAWDO-UHFFFAOYSA-K 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Eyeglasses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、亜塩素酸類化合物、並びにメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を含有する水性組成物に関する。更に詳しくは、本発明は、コンタクトレンズ用殺菌液、コンタクトレンズ用消毒液、コンタクトレンズ用洗浄液、コンタクトレンズ用すすぎ液、またはコンタクトレンズ用保存液である、前記水性組成物に関する。本発明は更に、コンタクトレンズ用多目的溶液(マルチパーパスソリューション)である、前記水性組成物に関する。本発明は更に、前記水性組成物を含有する点眼剤、特にドライアイ用の点眼剤に関する。 The present invention relates to an aqueous composition containing a chlorous acid compound and at least one component selected from the group consisting of menthol, menthone, camphor and borneol. More specifically, the present invention relates to the aqueous composition, which is a contact lens sterilizing solution, a contact lens disinfecting solution, a contact lens cleaning solution, a contact lens rinsing solution, or a contact lens preserving solution. The present invention further relates to the aqueous composition, which is a multipurpose solution for contact lenses (multipurpose solution). The present invention further relates to an eye drop containing the aqueous composition, particularly an eye drop for dry eye.
殺菌効果や洗浄効果が求められる分野は多岐にわたるが、中でも、コンタクトレンズに用いる眼科用組成物(コンタクトレンズ用組成物)の分野では、下記のような理由から特に、適切な殺菌力や洗浄力を有する組成物が望まれている。
コンタクトレンズは、眼や手指等に触れる際に微生物汚染を受け易いのみならず、レンズケースに保管中であっても、コンタクトレンズ保存液中で微生物が繁殖し、汚染され易い。そこで、コンタクトレンズ、特に微生物が繁殖し易い含水性コンタクトレンズ(以下、ソフトコンタクトレンズとも記載する)においては、日常的な消毒が義務付けられている。コンタクトレンズの消毒法は、煮沸消毒や、過酸化水素等の無機物を用いた殺菌方法が知られているが、前者は煮沸消毒器が必要であり、こすり洗いでコンタクトレンズの汚れを十分に落とした上で消毒する必要がある等、操作が煩雑であることが問題であり、さらに近年は煮沸できないコンタクトレンズが増えている。また後者は、中和が必要であるため操作が煩雑である事に加え、中和操作を忘れると眼障害が発生する等の問題点があった。このような問題を解決するため、コンタクトレンズ消毒法の中では、特に近年ポビドンヨードや塩化ポリドロニウム等の有機物を用いたコールド消毒法(化学消毒法)が急速に広まっている。この方法は中和が不要であり、コンタクトレンズの殺菌、洗浄、すすぎ、保存と言った多目的に使用することが可能であり操作も簡便であるが、殺菌力が弱かったり、消毒成分がレンズ表面に吸着して生体に毒性を示すことが懸念されるなどの問題点があった。
またコンタクトレンズは、涙液中のタンパク質、アミノ酸、脂質、糖類、塩類をはじめ、手指に付着した化粧品等の様々な物質により汚染されるため、日常の洗浄が不十分であると眼障害の原因となる事が知られている。例えば、近年の調査によりコンタクトレンズユーザーの約8%に眼障害が発生しているとの報告があるが、その患者の半数にはレンズ汚れが確認されており、明らかにレンズの汚れが眼障害の大きな要因として指摘できることが分かっている(例えば、非特許文献1参照)。
The fields where bactericidal and cleaning effects are required are diverse, but in particular, in the field of ophthalmic compositions used for contact lenses (compositions for contact lenses), the appropriate bactericidal and cleaning powers are particularly desirable for the following reasons. There is a desire for a composition having:
Contact lenses are not only susceptible to microbial contamination when touching the eyes or fingers, but also proliferate and contaminate in the contact lens preservation solution even when stored in the lens case. Therefore, daily disinfection is obligatory for contact lenses, particularly water-containing contact lenses (hereinafter also referred to as soft contact lenses) in which microorganisms are likely to propagate. As for the contact lens disinfection method, boiling disinfection and sterilization methods using inorganic substances such as hydrogen peroxide are known, but the former requires a boil disinfection device, and the contact lens is sufficiently cleaned by rubbing. In addition, there is a problem that the operation is complicated, for example, it is necessary to disinfect, and in recent years, contact lenses that cannot be boiled are increasing. In addition, the latter has a problem that, since neutralization is necessary, the operation is complicated, and eye damage occurs if the neutralization operation is forgotten. In order to solve such problems, among contact lens disinfection methods, in particular, in recent years, a cold disinfection method (chemical disinfection method) using an organic substance such as povidone iodine or polydronium chloride has been rapidly spreading. This method does not require neutralization and can be used for multiple purposes such as sterilization, cleaning, rinsing, and storage of contact lenses, and is easy to operate. There is a problem that it is feared that the substance is adsorbed on the body and shows toxicity to a living body.
In addition, contact lenses are contaminated by various substances such as proteins, amino acids, lipids, sugars, salts in tears, and cosmetics attached to the fingers. It is known that For example, according to a recent survey, it was reported that about 8% of contact lens users suffered from eye damage, but lens contamination was confirmed in half of the patients. It is known that this can be pointed out as a major factor (for example, see Non-Patent Document 1).
一方、亜塩素酸類化合物は、主に食品や水道水等を殺菌する目的で広く使用されている物質である。また、例えば亜塩素酸類化合物の他の用途として、眼科用組成物の分野において防腐成分として使用できる事も知られている(例えば、特許文献1参照)。さらに、亜塩素酸類化合物と遷移金属を用いて二酸化塩素を生成させる事によるコンタクトレンズ殺菌用の組成物(例えば、特許文献2参照)や、二酸化塩素を用いたコンタクトレンズ消毒剤組成物が開示されている(例えば、特許文献3参照)。
また、タンパク質やアミノ酸等の汚れに対する亜塩素酸類化合物の洗浄力については知られていない。そこで従来、亜塩素酸類化合物の殺菌効果と共に洗浄効果を持たせようとする組成物の場合、例えば特許文献2に記載されるように、殺菌力を持つ二酸化塩素と共に、別途酵素等を配合する事で洗浄力を付与するなどの工夫が必要であった。しかし、酵素の配合は、粘膜(特に眼粘膜)への適用を前提とする組成物においては、アレルギー反応等が懸念される等の問題点があった。
On the other hand, chlorous acid compounds are substances widely used mainly for the purpose of sterilizing food, tap water and the like. It is also known that, for example, as another use of chlorite compounds, it can be used as an antiseptic component in the field of ophthalmic compositions (see, for example, Patent Document 1). Further, a composition for sterilizing contact lenses by generating chlorine dioxide using a chlorous acid compound and a transition metal (for example, see Patent Document 2) and a contact lens disinfectant composition using chlorine dioxide are disclosed. (For example, refer to Patent Document 3).
In addition, the detergency of chlorite compounds against dirt such as proteins and amino acids is not known. Therefore, conventionally, in the case of a composition which has a cleaning effect as well as a sterilizing effect of a chlorite compound, for example, as described in Patent Document 2, an enzyme or the like is separately added together with chlorine dioxide having a sterilizing power. It was necessary to devise such as adding cleaning power. However, the formulation of the enzyme has a problem that an allergic reaction or the like is concerned in a composition premised on application to the mucous membrane (particularly the ocular mucosa).
更に、近年の人工的な空調環境のなかでの生活、およびコンピューター等の普及による注視する機会の増大、並びにコンタクトレンズの長時間の装用等に伴い、点眼剤、特にドライアイの症状に対する点眼剤が益々求められている。ここで、ドライアイとは、涙液の量的あるいは質的な異常により角結膜に障害が生じた状態をいい、涙液水層欠乏症、涙液油層欠乏症および涙液ムチン層欠乏症に大別される。従来の点眼剤には製剤中での細菌の繁殖を防ぐ目的で塩化ベンザルコニウム、グルコン酸クロルヘキシジン、メチルパラベンなどの界面活性作用のある防腐剤が含有されているが、かかる防腐剤は製剤中の細菌の細胞膜を破壊するのみならず、点眼後、涙液油層を破壊して涙液水層からの蒸発の増大を生じ、角結膜上皮の細胞膜の構造が破壊され、ひいては細菌の一層の繁殖を招き、角結膜障害を悪化させる。よって、ドライアイの症例に対する点眼剤としては、塩化ベンザルコニウム、グルコン酸クロルヘキシジン、メチルパラベンなどの界面活性剤作用のある防腐剤を含有しないことが好ましい(例えば、非特許文献2および3を参照)。加えて、亜塩素酸類化合物を有効成分とする点眼剤はこれまでに知られているが(例えば、特許文献1を参照)、点眼剤の使用時にまつげや手先が薬剤ボトルの先端部に接触することにより、涙液中のタンパク質等の汚染物質が点眼剤中に混入する恐れがある。この場合には、涙液中のタンパク質などの汚染物質により、使用する点眼剤中の亜塩素酸類化合物の殺菌活性などの低下が懸念される等の問題点があった。 Furthermore, eye drops, especially eye drops for dry eye symptoms due to the increasing life of people in the artificial air-conditioning environment in recent years, increasing opportunities to pay attention to the spread of computers, etc., and long-time use of contact lenses. Is increasingly required. As used herein, dry eye refers to a condition in which the keratoconjunctiva is damaged due to a quantitative or qualitative abnormality of tears, and is roughly classified into tear water layer deficiency, tear fluid layer deficiency, and tear fluid mucin layer deficiency. The Conventional eye drops contain preservatives having a surface active action such as benzalkonium chloride, chlorhexidine gluconate, and methylparaben for the purpose of preventing bacterial growth in the preparations. Not only does it destroy the cell membrane of bacteria, but also after tearing, it destroys the tear oil layer and causes an increase in evaporation from the tear water layer, destroying the structure of the cell membrane of the keratoconjunctival epithelium and thus further propagation of the bacteria. Invite and worsen keratoconjunctival disorders. Therefore, it is preferable not to contain a preservative having a surfactant action such as benzalkonium chloride, chlorhexidine gluconate, and methylparaben as an eye drop for dry eye cases (see, for example, Non-Patent Documents 2 and 3). . In addition, eye drops containing a chlorous acid compound as an active ingredient have been known so far (see, for example, Patent Document 1), but when using eye drops, the eyelashes and the hand touch the tip of the drug bottle. As a result, contaminants such as proteins in tears may be mixed into the eye drops. In this case, there has been a problem that there is a concern that the bactericidal activity of the chlorite compound in the eye drops used may be lowered due to contaminants such as proteins in tears.
ソフトコンタクトレンズのコールド消毒剤(化学消毒剤)としての、亜塩素酸類化合物を含有する水性組成物においては、薬理学的に許容されるpHにおいて十分な殺菌力が必要であるが、従来、亜塩素酸類化合物の十分な殺菌力は知られていなかった。さらに本発明者らは、涙液中のタンパク質、アミノ酸、脂質、糖類、塩類などがコンタクトレンズ表面や内部に付着し、経時的に酸化反応などの化学変化を受けて固着することで、コンタクトレンズが変色することを見出したが、このような化学変化によるコンタクトレンズの変色に対して、十分な洗浄力を有した水性組成物は存在しなかった。そこで本発明は、亜塩素酸類化合物を含有し、優れた殺菌力または洗浄力を有する水性組成物、中でも眼科用水性組成物やコンタクトレンズ用水性組成物を提供することを課題とする。本発明はまた、塩化ベンザルコニウム、グルコン酸クロルヘキシジン、メチルパラベンなどの界面活性作用のある防腐剤を含有せず、点眼剤の使用時に涙液中のタンパク質などが点眼剤中に混入した場合にもその殺菌活性が低下しない、亜塩素酸類化合物を含有する点眼剤を提供することを課題とする。 In an aqueous composition containing a chlorite compound as a cold disinfectant (chemical disinfectant) of a soft contact lens, sufficient bactericidal power is necessary at a pharmacologically acceptable pH. The sufficient bactericidal power of chloric acid compounds has not been known. Furthermore, the present inventors have attached the contact lens by attaching proteins, amino acids, lipids, saccharides, salts, etc. in the tear fluid to the contact lens surface or inside, and undergoing a chemical change such as an oxidation reaction over time. However, there was no aqueous composition having sufficient detergency against contact lens discoloration due to such a chemical change. Then, this invention makes it a subject to provide the aqueous composition which contains a chlorite compound, and has the outstanding bactericidal power or detergency, especially the ophthalmic aqueous composition and the aqueous composition for contact lenses. The present invention also does not contain a preservative having a surfactant activity such as benzalkonium chloride, chlorhexidine gluconate, methylparaben, etc., and even when proteins in tears are mixed in the eye drops when using eye drops. It is an object of the present invention to provide an eye drop containing a chlorous acid compound in which the bactericidal activity does not decrease.
本発明者らは、上記の目的を達成すべく鋭意研究を行った結果、亜塩素酸類化合物と共に、メントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を含有することにより、優れた殺菌力または洗浄力を有する水性組成物が得られることを見出し、本発明を完成した。すなわち本発明は、下記に掲げる発明を提供するものである。 As a result of intensive studies to achieve the above object, the present inventors have found that, together with a chlorite compound, at least one component selected from the group consisting of menthol, menthone, camphor and borneol is contained. The present inventors have found that an aqueous composition having excellent sterilizing power or detergency can be obtained and completed the present invention. That is, the present invention provides the following inventions.
[1]亜塩素酸類化合物、並びにメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を含有する水性組成物。 [1] An aqueous composition containing a chlorous acid compound and at least one component selected from the group consisting of menthol, menthone, camphor and borneol.
[2]更に等張化剤、pH調整剤および緩衝剤からなる群から選ばれる少なくとも1種を含有する、[1]に記載の水性組成物。 [2] The aqueous composition according to [1], further comprising at least one selected from the group consisting of an isotonic agent, a pH adjuster and a buffer.
[3]コンタクトレンズ用である[1]または[2]のいずれかに記載の水性組成物。 [3] The aqueous composition according to any one of [1] or [2], which is for contact lenses.
[4]コンタクトレンズ用殺菌液、コンタクトレンズ用消毒液、コンタクトレンズ用洗浄液、コンタクトレンズ用すすぎ液、またはコンタクトレンズ用保存液である、[1]〜[3]のいずれか1つに記載の水性組成物。 [4] The contact lens disinfection solution, the contact lens disinfection solution, the contact lens cleaning solution, the contact lens rinse solution, or the contact lens storage solution according to any one of [1] to [3] Aqueous composition.
[5]コンタクトレンズ用多目的溶液(マルチパーパスソリューション)である、[1]〜[4]のいずれか1つに記載の水性組成物。 [5] The aqueous composition according to any one of [1] to [4], which is a multipurpose solution for contact lenses (multipurpose solution).
[6]前記亜塩素酸類化合物が、亜塩素酸ナトリウム、亜塩素酸、亜塩素酸カリウム、亜塩素酸カルシウム、および亜塩素酸マグネシウムからなる群から選ばれる少なくとも1種である、[1]〜[5]のいずれか1つに記載の水性組成物。 [6] The chlorite compound is at least one selected from the group consisting of sodium chlorite, chlorite, potassium chlorite, calcium chlorite, and magnesium chlorite. [5] The aqueous composition according to any one of [5].
[7]水性組成物の総量に対して、亜塩素酸類化合物を総量で0.0001〜10(w/v)%、並びにメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を総量で0.00001〜5(w/v)%の割合で含有する、[1]〜[6]のいずれか1つに記載の水性組成物。 [7] The total amount of the chlorous acid compound is 0.0001 to 10 (w / v)% and at least one selected from the group consisting of menthol, menthone, camphor and borneol with respect to the total amount of the aqueous composition The aqueous composition according to any one of [1] to [6], which contains the components in a ratio of 0.00001 to 5 (w / v)% in total.
[8]亜塩素酸類化合物の総量100重量部に対して、メントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を総量で0.01〜500000重量部の割合で含有する、[1]〜[7]のいずれか1つに記載の水性組成物。 [8] Containing at least one component selected from the group consisting of menthol, menthone, camphor and borneol in a total amount of 0.01 to 500,000 parts by weight with respect to 100 parts by weight of the total amount of chlorous acid compounds. , [1] to [7] The aqueous composition according to any one of [7].
[9]出発物質として亜塩素酸および/またはその塩、並びにメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を配合して調製する水性組成物。 [9] An aqueous composition prepared by blending chlorous acid and / or a salt thereof as a starting material and at least one component selected from the group consisting of menthol, menthone, camphor and borneol.
[10]更に等張化剤、pH調整剤および緩衝剤からなる群から選ばれる少なくとも1種を配合する、[9]に記載の水性組成物。 [10] The aqueous composition according to [9], further comprising at least one selected from the group consisting of an isotonic agent, a pH adjuster and a buffer.
[11]水性組成物の総量に対して、亜塩素酸および/またはその塩を総量で0.0001〜10(w/v)%、並びにメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を総量で0.00001〜5(w/v)%の割合で配合する、[9]または[10]のいずれかに記載の水性組成物。 [11] With respect to the total amount of the aqueous composition, chlorous acid and / or a salt thereof is selected from the group consisting of 0.0001 to 10 (w / v)% in total and menthol, menthone, camphor and borneol. The aqueous composition according to any one of [9] and [10], wherein at least one component is blended in a total amount of 0.00001 to 5 (w / v)%.
[12]亜塩素酸および/またはその塩の総量100重量部に対して、メントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を総量で0.01〜500000重量部の割合で配合する、[9]〜[11]のいずれか1つに記載の水性組成物。 [12] The total amount of at least one component selected from the group consisting of menthol, menthone, camphor and borneol is 0.01 to 500,000 parts by weight with respect to 100 parts by weight of the total amount of chlorous acid and / or a salt thereof. The aqueous composition according to any one of [9] to [11], which is blended in a proportion.
[13]コンタクトレンズ用である[9]〜[12]のいずれか1つに記載の水性組成物。 [13] The aqueous composition according to any one of [9] to [12], which is for contact lenses.
[14]コンタクトレンズ用殺菌液、コンタクトレンズ用消毒液、コンタクトレンズ用洗浄液、コンタクトレンズ用すすぎ液、またはコンタクトレンズ用保存液である、[9]〜[13]のいずれか1つに記載の水性組成物。 [14] The contact lens disinfection solution, the contact lens disinfection solution, the contact lens cleaning solution, the contact lens rinse solution, or the contact lens storage solution according to any one of [9] to [13] Aqueous composition.
[15]コンタクトレンズ用多目的溶液(マルチパーパスソリューション)である、[9]〜[14]のいずれか1つに記載の水性組成物。 [15] The aqueous composition according to any one of [9] to [14], which is a multipurpose solution for contact lenses (multipurpose solution).
[16][1]〜[15]のいずれか1つに記載の水性組成物を含む、微生物を殺菌するための薬剤。 [16] A drug for sterilizing microorganisms, comprising the aqueous composition according to any one of [1] to [15].
[17]亜塩素酸類化合物、並びにメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分の微生物に対する殺菌力が、各単独成分に比べて高い効果を有する、[16]に記載の薬剤。 [17] The sterilizing power against microorganisms of at least one component selected from the group consisting of chlorous acid compounds and menthol, menthone, camphor and borneol has a higher effect than each individual component in [16] The drug described.
[18]微生物が、細菌および/または真菌である、[16]または[17]のいずれかに記載の薬剤。 [18] The drug according to any of [16] or [17], wherein the microorganism is a bacterium and / or a fungus.
[19]微生物が、カンジダ・アルビカンス、アスペルギルス・ニガー、スタフィロコッカス・アウレウス、シュードモナス・エルギノーサ、セラチア・マルセセンス、フザリウム、ヘルペスウイルス、アデノウイルス、エンテロウイルス、およびアカントアメーバからなる群から選ばれる、[16]または[17]のいずれかに記載の薬剤。 [19] The microorganism is selected from the group consisting of Candida albicans, Aspergillus niger, Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Fusarium, herpesvirus, adenovirus, enterovirus, and Acanthamoeba [16] ] Or the drug according to any one of [17].
[20]亜塩素酸類化合物を含有する水性組成物にメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を配合することを特徴とする、亜塩素酸類化合物の殺菌力の増強方法。 [20] The bactericidal activity of a chlorite compound, characterized in that the aqueous composition containing a chlorite compound contains at least one component selected from the group consisting of menthol, menthone, camphor and borneol. Enhancement method.
[21]亜塩素酸類化合物を含有する水性組成物にメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を配合することを特徴とする、亜塩素酸類化合物の洗浄力の増強方法。 [21] The detergency of a chlorite compound, characterized in that the aqueous composition containing a chlorite compound contains at least one component selected from the group consisting of menthol, menthone, camphor and borneol. Enhancement method.
本発明によれば、亜塩素酸類化合物、並びにメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を組み合わせることにより、それら各構成成分の単独では到底得られない優れた殺菌力を示す水性組成物を提供することができる。特に、コンタクトレンズ用組成物の分野においては、本発明によれば、高い殺菌力を示すのみならず、殺菌力低下の原因となりうる汚れに対する洗浄効果が高いため、例え過剰な汚れの付着したコンタクトレンズに用いた場合でも安定した殺菌力を発揮することができる。また、本発明の水性組成物をコンタクトレンズケア用組成物、中でもコールド消毒剤として用いた場合には、亜塩素酸類化合物は眼内では涙液により中和されるため、従来の有機物を殺菌成分として用いた製剤のように有効成分吸着による眼障害や不十分な殺菌力による感染症を引き起こしたりといった問題点が解消される。また、本発明は、従来の過酸化水素を用いたコンタクトレンズ消毒剤のような中和作業が必要ない為、中和忘れによる眼障害という懸念も無い。さらに、本発明の組成物は、高い殺菌力と洗浄力を有する故に、従来のように微生物や汚れを物理的に除去するための「こすり洗い」が不要であり、それによりこすり洗い時のコンタクトレンズ破損の恐れもなく、かつ消費者にとって利便性が高い。
加えて、本発明の亜塩素酸類化合物を含有する水性組成物を含む点眼剤は、涙液中のタンパク質などの汚染物質の共存下でも有効成分である亜塩素酸類化合物の殺菌力が低下せず、塩化ベンザルコニウム、グルコン酸クロルヘキシジン、メチルパラベンなどの界面活性作用のある防腐剤を含まないため、ドライアイ等に有効である。
According to the present invention, by combining at least one component selected from the group consisting of chlorous acid compounds and menthol, menthone, camphor and borneol, excellent sterilization that cannot be obtained by each of these components alone. An aqueous composition that exhibits strength can be provided. In particular, in the field of contact lens compositions, according to the present invention, not only exhibits high sterilizing power, but also has a high cleaning effect on dirt that can cause a decrease in sterilizing power. Even when used in a lens, stable sterilizing power can be exhibited. In addition, when the aqueous composition of the present invention is used as a contact lens care composition, particularly as a cold disinfectant, chlorite compounds are neutralized by tears in the eye, so that conventional organic substances can be used as a bactericidal component. The problems such as eye damage caused by adsorption of active ingredients and infection caused by insufficient bactericidal power are eliminated as in the preparation used. In addition, since the present invention does not require neutralization work unlike the conventional contact lens disinfectant using hydrogen peroxide, there is no concern of eye damage due to forgetting neutralization. Furthermore, since the composition of the present invention has high bactericidal and detergency properties, it does not require “rubbing” for physically removing microorganisms and dirt as in the prior art, so that contact at the time of rubbing is possible. There is no fear of damage to the lens and it is convenient for consumers.
In addition, the eye drop containing the aqueous composition containing the chlorite compound of the present invention does not reduce the bactericidal activity of the chlorite compound, which is an active ingredient, even in the presence of contaminants such as proteins in tears. It does not contain preservatives having surface activity such as benzalkonium chloride, chlorhexidine gluconate, and methylparaben, and is effective for dry eyes and the like.
本願明細書および添付する特許請求の範囲中で使用する用語について以下に説明する。 Terms used in the present specification and appended claims are described below.
本発明で用いる用語「亜塩素酸類化合物」とは、亜塩素酸および/またはその塩を配合した水性組成物中に発生し得る化合物を示す包括的表現である。亜塩素酸および/またはその塩を配合した水性組成物中に発生し得る化合物としては、亜塩素酸(化学式HClO2で示される化合物)および/またはその塩、二酸化塩素、二酸化二塩素、塩素、次亜塩素酸および/またはその塩、並びに塩素イオン、次亜塩素酸イオン、亜塩素酸イオン、塩素酸イオン、および過塩素酸イオンなどが例示されるものの、これらに限らない。亜塩素酸の塩としては、亜塩素酸のアルカリ金属塩、アルカリ土類金属塩、銅塩、鉛塩、アンモニウム塩などが例示されるものの、これらに限定されない。好ましい亜塩素酸の塩としては、亜塩素酸のアルカリ金属塩、アルカリ土類金属塩である。さらに好ましい亜塩素酸の塩としては、亜塩素酸ナトリウム、亜塩素酸カリウム、亜塩素酸カルシウム、亜塩素酸マグネシウムであり、特に好ましくは、亜塩素酸ナトリウムである。また次亜塩素酸の塩としては、次亜塩素酸のアルカリ金属塩、アルカリ土類金属塩、銅塩、鉛塩、アンモニウム塩などが例示されるものの、これらに限定されない。好ましい次亜塩素酸の塩としては、次亜塩素酸のアルカリ金属塩、アルカリ土類金属塩である。さらに好ましい次亜塩素酸の塩としては、次亜塩素酸ナトリウム、次亜塩素酸カリウム、次亜塩素酸カルシウム、次亜塩素酸マグネシウムであり、特に好ましくは、次亜塩素酸ナトリウムである。 The term “chlorous acid compound” used in the present invention is a comprehensive expression indicating a compound that can be generated in an aqueous composition containing chlorous acid and / or a salt thereof. Compounds that can be generated in an aqueous composition containing chlorous acid and / or a salt thereof include chlorous acid (a compound represented by the chemical formula HClO 2 ) and / or a salt thereof, chlorine dioxide, dichlorine dioxide, chlorine, Examples include, but are not limited to, hypochlorous acid and / or salts thereof, and chlorine ions, hypochlorite ions, chlorite ions, chlorate ions, and perchlorate ions. Examples of chlorous acid salts include, but are not limited to, alkali metal salts, alkaline earth metal salts, copper salts, lead salts, and ammonium salts of chlorous acid. Preferred salts of chlorous acid are alkali metal salts and alkaline earth metal salts of chlorous acid. More preferred salts of chlorite are sodium chlorite, potassium chlorite, calcium chlorite, and magnesium chlorite, and particularly preferred is sodium chlorite. Examples of hypochlorous acid salts include, but are not limited to, alkali metal salts, alkaline earth metal salts, copper salts, lead salts and ammonium salts of hypochlorous acid. Preferred salts of hypochlorous acid are alkali metal salts and alkaline earth metal salts of hypochlorous acid. More preferable salts of hypochlorous acid are sodium hypochlorite, potassium hypochlorite, calcium hypochlorite, and magnesium hypochlorite, and sodium hypochlorite is particularly preferable.
本発明で用いる用語「メントール」、「メントン」、「カンフル」および「ボルネオール」とは、それぞれ有機化学分野において知られる化合物を意味する。それら化合物は各々、それらの各エナンチオマー、ラセミ体、またはエナンチオマー混合物を含む。l−メントールが最も好ましい。これらの化合物は、出発物質としてこれら化合物を含有する精油として本発明の水性組成物中に配合することもできる。これらの化合物はまた通常、清涼化剤としても使用することができる。 The terms “menthol”, “mentholone”, “camphor” and “borneol” used in the present invention mean compounds known in the field of organic chemistry, respectively. Each of these compounds includes their respective enantiomer, racemate, or mixture of enantiomers. l-menthol is most preferred. These compounds can also be incorporated into the aqueous composition of the present invention as essential oils containing these compounds as starting materials. These compounds can also usually be used as cooling agents.
本明細書中、「%」と言う表記は、特記しない限りw/v%、即ち水性組成物100mLに溶けている各成分(溶質)の重量gを意味するものである。 In the present specification, the notation “%” means w / v%, that is, the weight g of each component (solute) dissolved in 100 mL of the aqueous composition unless otherwise specified.
本発明で用いる用語「水性組成物」とは、組成物の総量に対して、水を通常20%以上、好ましくは50%以上、より好ましくは80%以上、特に好ましくは90%以上の割合で含有する組成物である。使用する水は、蒸留水、精製水または滅菌精製水であることが好ましい。 The term “aqueous composition” used in the present invention means that water is usually 20% or more, preferably 50% or more, more preferably 80% or more, and particularly preferably 90% or more with respect to the total amount of the composition. It is a composition to contain. The water to be used is preferably distilled water, purified water or sterilized purified water.
本発明で用いる用語「コンタクトレンズ用多目的溶液(マルチパーパスソリューション)」とは、コンタクトレンズの洗浄、すすぎ、保存、および消毒の機能から選ばれる機能の内の少なくとも2以上の機能を併せ持った水性組成物のことである。 The term “multipurpose solution for contact lenses” used in the present invention means an aqueous composition having at least two or more functions selected from the functions of cleaning, rinsing, storing and disinfecting contact lenses. It is a thing.
本発明の水性組成物において含まれる亜塩素酸類化合物の含有量は、本発明の効果を奏すれば特に制限されないが、水性組成物の総量に対して、通常0.0001〜10(w/v)%、好ましくは0.0005〜1(w/v)%、特に好ましくは0.001〜0.1(w/v)%の割合であり、さらに特に好ましくは0.002〜0.01(w/v)%の割合である。また、本発明の水性組成物において含まれる、メントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分の含有量は、本発明の効果を奏すれば特に制限されないが、水性組成物の総量に対して、通常0.00001〜5(w/v)%、好ましくは0.00005〜1(w/v)%、特に好ましくは0.0001〜0.2(w/v)%の割合である。 The content of the chlorous acid compound contained in the aqueous composition of the present invention is not particularly limited as long as the effects of the present invention are exerted, but is usually 0.0001 to 10 (w / v with respect to the total amount of the aqueous composition). )%, Preferably 0.0005 to 1 (w / v)%, particularly preferably 0.001 to 0.1 (w / v)%, and still more preferably 0.002 to 0.01 (w / v)%. The ratio is w / v)%. In addition, the content of at least one component selected from the group consisting of menthol, menthone, camphor and borneol contained in the aqueous composition of the present invention is not particularly limited as long as the effect of the present invention is achieved, 0.00001 to 5 (w / v)%, preferably 0.00005 to 1 (w / v)%, particularly preferably 0.0001 to 0.2 (w / v), based on the total amount of the composition %.
本発明の水性組成物において含まれる、メントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分の含有量は、本発明の効果を奏すれば特に制限されないが、亜塩素酸類化合物の総量100重量部に対して、メントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分が、総量で0.01〜500000重量部の割合;好ましくは、総量で0.05〜100000重量部の割合;更に好ましくは、0.1〜20000重量部の割合である。 The content of at least one component selected from the group consisting of menthol, menthone, camphor and borneol contained in the aqueous composition of the present invention is not particularly limited as long as the effects of the present invention are exhibited, but chlorite acids A ratio of 0.01 to 500,000 parts by weight of the total amount of at least one component selected from the group consisting of menthol, menthone, camphor and borneol with respect to 100 parts by weight of the total amount of the compound; A ratio of 05 to 100,000 parts by weight; more preferably, a ratio of 0.1 to 20,000 parts by weight.
本発明の水性組成物は必要に応じて、生体に許容される範囲内のpHおよび/または浸透圧に調節される。本発明の水性組成物は、高い殺菌力や洗浄力を有し、中性付近で十分に発明の効果を奏するため、コンタクトレンズへの悪影響が少なく、また該水性組成物からコンタクトレンズを取り出して目に装着した際の使用感も好適である。本発明の水性組成物の許容されるpHは、通常5〜10、好ましくは5.2〜8.5、より好ましくは5.5〜7.5である。また、生理食塩液に対する浸透圧比は、通常0.3〜4.2、好ましくは0.3〜2.1、特に好ましくは0.5〜1.4程度である。尚、浸透圧比の測定方法は、第15改正日本薬局方 凝固点降下法を参考にして実施する。pHや浸透圧の調節は、後述のpH調整剤、等張化剤、緩衝剤等を用いて、当該技術分野で既知の方法で行うことができる。 The aqueous composition of the present invention is adjusted to a pH and / or osmotic pressure within a range acceptable by a living body as necessary. The aqueous composition of the present invention has high bactericidal power and detergency, and exhibits the effects of the invention sufficiently near neutrality, so there is little adverse effect on the contact lens, and the contact lens is taken out from the aqueous composition. The feeling of use when worn on the eyes is also suitable. The acceptable pH of the aqueous composition of the present invention is usually 5 to 10, preferably 5.2 to 8.5, more preferably 5.5 to 7.5. Moreover, the osmotic pressure ratio with respect to the physiological saline is usually about 0.3 to 4.2, preferably about 0.3 to 2.1, and particularly preferably about 0.5 to 1.4. The osmotic pressure ratio is measured with reference to the 15th revised Japanese Pharmacopoeia freezing point depression method. The pH and osmotic pressure can be adjusted by a method known in the art using a pH adjusting agent, an isotonic agent, a buffering agent and the like described later.
本発明で用いる用語「等張化剤」としては、薬理学的に許容し得る等張化剤が挙げられ、例えば塩化カリウム、塩化ナトリウムなどの無機塩類、および酢酸カリウム、酢酸ナトリウムなどの有機塩類、またはそれらの組み合わせを含むが、これらに限定されない。塩化ナトリウムが特に好ましい。本発明の水性組成物中の等張化剤の含有量は、等張化剤の種類などによって異なるので一概に規定できないが、水性組成物の総量に対し、これらが総量で、通常0.01〜5.0(w/v)%、好ましくは0.1〜2.0(w/v)%、特に好ましくは0.1〜1.5(w/v)%で用いられる。 The term “isotonic agent” used in the present invention includes pharmacologically acceptable isotonic agents, for example, inorganic salts such as potassium chloride and sodium chloride, and organic salts such as potassium acetate and sodium acetate. Or a combination thereof, but is not limited thereto. Sodium chloride is particularly preferred. The content of the tonicity agent in the aqueous composition of the present invention varies depending on the type of tonicity agent and the like, and thus cannot be specified unconditionally. However, these are the total amount relative to the total amount of the aqueous composition, usually 0.01. To 5.0 (w / v)%, preferably 0.1 to 2.0 (w / v)%, particularly preferably 0.1 to 1.5 (w / v)%.
本発明で用いる用語「pH調整剤」としては、薬理学的に許容し得るpH調整剤が挙げられ、例えば塩酸、水酸化ナトリウム、炭酸水素ナトリウム、炭酸ナトリウムなどの無機酸もしくは無機塩基;または、リン酸、ポリリン酸、ホウ酸、ホウ砂、酢酸、トリエタノールアミン、モノエタノールアミンなどの有機酸もしくは有機塩基、またはそれらの組み合わせを含むが、これらに限定されない。 The term “pH adjuster” used in the present invention includes a pharmacologically acceptable pH adjuster, for example, an inorganic acid or an inorganic base such as hydrochloric acid, sodium hydroxide, sodium bicarbonate, sodium carbonate; or Including, but not limited to, organic acids or bases such as phosphoric acid, polyphosphoric acid, boric acid, borax, acetic acid, triethanolamine, monoethanolamine, or combinations thereof.
本発明で用いる用語「緩衝剤」としては、薬理学的に許容し得る緩衝剤が挙げられ、例えば、ホウ酸緩衝剤、リン酸緩衝剤、クエン酸緩衝剤、酢酸緩衝剤、炭酸緩衝剤、アミノエチルスルホン酸、アスパラギン酸またはその塩(アスパラギン酸カリウム、アスパラギン酸マグネシウムなど)、イプシロン−アミノカプロン酸、HEPES、MOPSなどが挙げられ、好ましくはホウ酸緩衝剤、リン酸緩衝剤、クエン酸緩衝剤である。ホウ酸緩衝剤、リン酸緩衝剤、クエン酸緩衝剤、酢酸緩衝剤、炭酸緩衝剤としては、それぞれホウ酸またはその塩(テトラホウ酸カリウム、ホウ酸ナトリウム、ホウ砂、メタホウ酸カリウムなど)、リン酸またはその塩(リン酸水素二ナトリウム、リン酸二水素ナトリウム、リン酸水素二カリウム、もしくはリン酸二水素カリウム、またはそれらの水和物など)、クエン酸またはその塩(クエン酸ナトリウム、クエン酸カリウムなど)、酢酸またはその塩(酢酸カリウム、酢酸ナトリウム)、炭酸またはその塩(炭酸ナトリウム、炭酸水素ナトリウム)またはそれらの組み合わせを含むが、これらに限定されない。 The term “buffer” used in the present invention includes a pharmacologically acceptable buffer, such as borate buffer, phosphate buffer, citrate buffer, acetate buffer, carbonate buffer, Aminoethylsulfonic acid, aspartic acid or a salt thereof (potassium aspartate, magnesium aspartate, etc.), epsilon-aminocaproic acid, HEPES, MOPS, etc. are preferable, preferably borate buffer, phosphate buffer, citrate buffer It is. As borate buffer, phosphate buffer, citrate buffer, acetate buffer, and carbonate buffer, boric acid or its salts (potassium tetraborate, sodium borate, borax, potassium metaborate, etc.), phosphorus, respectively Acids or salts thereof (such as disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, or hydrates thereof), citric acid or salts thereof (sodium citrate, Potassium acetate, etc.), acetic acid or a salt thereof (potassium acetate, sodium acetate), carbonic acid or a salt thereof (sodium carbonate, sodium bicarbonate) or a combination thereof.
本発明で使用する用語「微生物」とは、主に人体に悪影響を及ぼす可能性のある微生物を示す。中でも特に、本発明の水性組成物は、眼科的に、例えばコンタクトレンズを介して、眼障害を引き起こすおそれがある微生物に対して優れた殺菌力を示し、それらの微生物としては、例えば細菌、真菌、ウイルスまたはアメーバなどの原生生物などが挙げられる。本明細書中に記載の試験例で使用した菌種は、スタンドアロン試験で通常使用される菌種を参考にして選出されたものである。なお、スタンドアロン試験とは、米国食品医薬品局(FDA)眼科装置部門で作成されたコンタクトレンズケア製品の市販前通知ガイダンス文書(通称:510k)によるコンタクトレンズケア製品の消毒効果試験法である。本発明の水性組成物が、特に好適に殺菌効果を発揮する具体的な微生物としては、例えばスタフィロコッカス・アウレウス(Staphylococcus aureus: 例えばATCC 6538)、シュードモナス・エルギノーサ(Pseudomonas aeruginosa: 例えばATCC 9027)、セラチア・マルセセンス(Serratia marcescens: 例えばATCC 13880)などの細菌、カンジダ・アルビカンス(Candida albicans: 例えばATCC 10231)、アスペルギルス・ニガー(Aspergillus niger)、フザリウム(Fusarium)などの真菌、ヘルペスウイルス(Herpes simplex Type 1)、アデノウイルス(Adenovirus)、エンテロウイルス(enterovirus)などのウイルス、またはアカント・アメーバ(Acanthamoeba)のような原生生物が挙げられるが、これらに限定されない。スタフィロコッカス・アウレウスおよびカンジダ・アルビカンスに対しては、特に優れた殺菌効果を示す為、好ましい。 The term “microorganism” used in the present invention refers to a microorganism that may have an adverse effect mainly on the human body. In particular, the aqueous composition of the present invention exhibits an excellent bactericidal power against microorganisms that may cause eye damage, ophthalmically, for example, via contact lenses. Examples of these microorganisms include bacteria and fungi. And protists such as viruses or amoeba. The bacterial species used in the test examples described in this specification are selected with reference to the bacterial species usually used in the stand-alone test. The stand-alone test is a test method for the disinfection effect of a contact lens care product according to a pre-market notification guidance document (common name: 510k) of a contact lens care product prepared by the US Food and Drug Administration (FDA) ophthalmic device department. Specific examples of the microorganism in which the aqueous composition of the present invention particularly preferably exhibits a bactericidal effect include, for example, Staphylococcus aureus (for example, ATCC 6538), Pseudomonas aeruginosa (for example, ATCC 9027), Bacteria such as Serratia marcescens (e.g. ATCC 13880), fungi such as Candida albicans (e.g. ATCC 10231), Aspergillus niger, Fusarium, Herpes virus (Herpes simplex Type 1) ), Viruses such as Adenovirus, enterovirus, or protists such as Acanthamoeba, but are not limited thereto. Staphylococcus aureus and Candida albicans are preferable because they exhibit a particularly excellent bactericidal effect.
本発明で使用する用語「コンタクトレンズ」とは、特記しない限り、ハード、酸素透過性ハード、ソフト、シリコンハイドロゲルレンズ等のあらゆるタイプのコンタクトレンズを包含する意味で用いる。ソフトコンタクトレンズ、シリコンハイドロゲルレンズが特に好ましい。また、本発明で使用する用語「ソフトコンタクトレンズ分類」とは、平成11年3月31日付医薬審第645号厚生労働省(当時の厚生省)医薬安全局審査管理課長通知「ソフトコンタクトレンズ及びソフトコンタクトレンズ用消毒剤の製造(輸入)承認申請に際し添付すべき資料の取り扱い等について」において規定された「ソフトコンタクトレンズの分類方法について」に基づくソフトコンタクトレンズの分類であり、該分類において、グループIVに属するソフトコンタクトレンズは、含水率が50%以上であり、原材料ポリマーの構成モノマーのうち陰イオンを有するモノマーのモル%が1%以上であることを共通の性質として有する。尚、本分類はFDA(米国食品医薬品局)が行なっているソフトコンタクトレンズの分類方法に従っている。 The term “contact lens” used in the present invention is used to include all types of contact lenses such as hard, oxygen-permeable hard, soft, and silicon hydrogel lenses unless otherwise specified. Soft contact lenses and silicon hydrogel lenses are particularly preferred. In addition, the term “soft contact lens classification” used in the present invention is the “Pharmaceutical Examination No. 645 dated March 31, 1999” by the Ministry of Health, Labor and Welfare (Ministry of Health, Labor and Welfare), Director of the Examination Management Division, “Soft Contact Lens and Soft Contact”. This is a soft contact lens classification based on “How to classify soft contact lenses” defined in “Handling of Materials to be Attached when Applying for Manufacturing (Import) Approval of Lens Disinfectant”. The soft contact lens belonging to No. 1 has a common property that the moisture content is 50% or more and the mole% of the monomer having an anion among the constituent monomers of the raw material polymer is 1% or more. This classification follows the classification method for soft contact lenses performed by the FDA (Food and Drug Administration).
製造方法
本発明の水性組成物の製造方法は、当該技術分野における常法により、無菌環境下、予めメントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分、および必要に応じて等張化剤等の他の成分を水性媒質中で配合して調製した溶液に、亜塩素酸類化合物を配合する工程を含む。必要に応じて、pH調整剤を加えることによって、水溶液のpHを生体に許容される範囲内のpHに調製する工程を含む。次いで、得られた溶液を無菌環境下、ろ過滅菌処理し、洗浄滅菌済みの容器に無菌充填する工程により、本発明の水性組成物を製造することができる。但し、この方法に限定されない。
Production method The production method of the aqueous composition of the present invention is carried out according to a conventional method in the art, at least one component selected from the group consisting of menthol, menthone, camphor and borneol in advance in an aseptic environment, and as necessary. A step of blending a chlorous acid compound with a solution prepared by blending other components such as an isotonic agent in an aqueous medium. If necessary, it includes a step of adjusting the pH of the aqueous solution to a pH within the range acceptable by the living body by adding a pH adjusting agent. Next, the aqueous composition of the present invention can be produced by a step of subjecting the obtained solution to a filter sterilization treatment in an aseptic environment and aseptically filling a container that has been washed and sterilized. However, it is not limited to this method.
本発明の水性組成物は、本発明の効果を妨げない限り、上記の成分に加えて、各種用途に応じて、種々の活性成分または薬効成分(薬理活性成分および生理活性成分を含む)や添加剤(界面活性剤、増粘剤、キレート剤、安定化剤、防腐剤・保存剤、香料等)を組み合わせて含有してもよい。このような成分は、眼刺激等の問題がない濃度範囲内で適宜配合することができ、成分の種類は特に制限されないが具体的には以下のものを例示できる。 As long as the effects of the present invention are not hindered, the aqueous composition of the present invention includes various active ingredients or medicinal ingredients (including pharmacologically active ingredients and physiologically active ingredients) and additives in addition to the above-mentioned components, depending on various uses. Agents (surfactants, thickeners, chelating agents, stabilizers, preservatives / preservatives, fragrances, etc.) may be contained in combination. Such components can be appropriately blended within a concentration range in which there are no problems such as eye irritation, and the types of the components are not particularly limited, but specific examples include the following.
前記医薬活性成分としては、例えば、充血除去成分、筋調整機能剤、抗炎症・収斂剤、抗ヒスタミン剤、ビタミン類、サルファ剤、抗アレルギー剤、細胞賦活剤、殺菌剤等を挙げることができ、具体的には、エピネフリン、塩酸エピネフリン、塩酸エフェドリン、塩酸テトラヒドロゾリン、塩酸オキシメタゾリン、塩酸ナファゾリン、硝酸ナファゾリン、塩酸フェニレフリン、d l −塩酸メチルエフェドリン等の充血除去成分、メチル硫酸ネオスチグミン等の筋調整機能剤、イプシロン− アミノカプロン酸、アラントイン、塩化ベルベリン、硫酸ベルベリン、アズレンスルホン酸ナトリウム、グリチルリチン酸二カリウム、硫酸亜鉛、乳酸亜鉛、塩化リゾチーム等の消炎・収斂成分、塩酸ジフェンヒドラミン、マレイン酸クロルフェニラミン等の抗ヒスタミン剤、フラビンアデニンジヌクレオチドナトリウム、シアノコバラミン、酢酸レチノール、パルミチン酸レチノール、塩酸ピリドキシン、パンテノール、パントテン酸カルシウム、パントテン酸ナトリウム、酢酸トコフェロール、リボフラビン等のビタミン類、スルファメトキサゾール、スルファメトキサゾールナトリウム、スルフイソキサゾール、スルフイソミジンナトリウム等のサルファ剤、クロモグリク酸ナトリウム、フマル酸ケトチフェン、アンレキサノクス、ペミロラストカリウム、トラニラスト等の抗アレルギー剤、L - アスパラギン酸カリウム、L - アスパラギン酸マグネシウム、L - アスパラギン酸マグネシウム・カリウム、アミノエチルスルホン酸、コンドロイチン硫酸ナトリウム等の細胞賦活剤、ポリヘキサメチレンビグアニドや塩化ポリドロニウムなどの殺菌剤が挙げられるが、これらに限定されない。 Examples of the pharmaceutically active ingredient include a decongestant, a muscle regulating agent, an anti-inflammatory / astringent, an antihistamine, vitamins, sulfa, an antiallergic agent, a cell activator, a bactericide, and the like. Include epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, tetrahydrozoline hydrochloride, oxymetazoline hydrochloride, naphazoline hydrochloride, naphazoline hydrochloride, phenylephrine hydrochloride, dl-methylephedrine hydrochloride and other muscle regulating agents such as neostigmine methyl sulfate, Epsilon-aminocaproic acid, allantoin, berberine chloride, berberine sulfate, sodium azulenesulfonate, dipotassium glycyrrhizinate, zinc sulfate, zinc lactate, lysozyme and other anti-inflammatory and astringent components, diphenhydramine hydrochloride, chlorpheniramise maleate Antihistamines such as flavin adenine dinucleotide sodium, cyanocobalamin, retinol acetate, retinol palmitate, pyridoxine hydrochloride, panthenol, calcium pantothenate, sodium pantothenate, tocopherol acetate, riboflavin, vitamins such as sulfamethoxazole, sulfa Sulpha drugs such as sodium methoxazole, sulfisoxazole, sodium sulfisomidine, antiallergic drugs such as sodium cromoglycate, ketotifen fumarate, amlexanox, pemirolast potassium, tranilast, L-potassium aspartate, L- Cell activators such as magnesium aspartate, L-magnesium and potassium aspartate, aminoethylsulfonic acid, sodium chondroitin sulfate, poly Kisa fungicides such as biguanide or chloride Poridoroniumu including but not limited to.
界面活性剤としては、ポロクサマー4 0 7、ポロクサマー2 3 5、ポロクサマー1 8 8などのポリオキシエチレン( 以下、P O E と略す) − ポリオキシプロピレン( 以下、P O P と略す) ブロックコポリマー) 、ポロキサミンなどのエチレンジアミンのP O E -P O P ブロックコポリマー付加物、モノラウリル酸P O E ( 2 0 )ソルビタン( ポリソルベート2 0 )、モノオレイン酸P O E ( 2 0 )ソルビタン( ポリソルベート80) 、ポリソルベート6 0などのP O E ソルビタン脂肪酸エステル類、P O E ( 6 0 )硬化ヒマシ油などのP O E 硬化ヒマシ油類、P O E ( 9 )ラウリルエーテルなどのP O E アルキルエーテル類、P O E ( 2 0 )P O P ( 4 )セチルエーテルなどのP O E ・P O P アルキルエーテル類、P O E ( 1 0 )ノニルフェニルエーテルなどのP O E アルキルフェニルエーテル類、P O E( 1 0 )ノニルフェニルエーテル等のP O E アルキルフェニルエーテル類、ステアリン酸ポリオキシルなどの非イオン性界面活性剤; アルキルジアミノエチルグリシンなどのグリシン型、ラウリルジメチルアミノ酢酸ベタインなどの酢酸ベタイン型、イミダゾリン型などの両性界面活性剤; アルキルエーテルカルボン酸塩、テトラデセンスルホン酸ナトリウムなどのスルホン酸塩、ラウリル硫酸ナトリウムなどのアルキル硫酸塩、N − ココイルメチルタウリンナトリウムなどのN − アシルタウリン塩、P O E ( 1 0 )ラウリルエーテルリン酸ナトリウムなどのP O E アルキルエーテルリン酸及びその塩、ラウロイルメチルアラニンナトリウムなどのN − アシルアミノ酸塩、P O E ( 3 )ラウリルエーテル硫酸ナトリウムなどのP O E アルキルエーテル硫酸塩、α − オレフィンスルホン酸塩などの陰イオン性界面活性剤; アルキルアミン塩、塩化ベンザルコニウム、塩化ベンゼトニウムなどのアルキル4 級アンモニウム塩、塩化セチルピリジニウム、臭化セチルピリジニウムなどのアルキルピリジニウム塩などの陽イオン性界面活性剤などが挙げられ、好ましくは非イオン性界面活性剤である。さらに、P O E−P O Pブロックコポリマー、P O E ソルビタン脂肪酸エステル類、P O E 硬化ヒマシ油類が好ましく、中でもポロクサマー4 0 7、ポリソルベート8 0、P O E ( 6 0 )硬化ヒマシ油が好ましく、特に好ましくはポリソルベート8 0である。 Examples of the surfactant include polyoxyethylene (hereinafter, abbreviated as P O E) such as poloxamer 4 07, poloxamer 2 3 5 and poloxamer 1 8 8-polyoxypropylene (hereinafter abbreviated as P O P) block copolymer) POE-POP block copolymer adduct of ethylenediamine such as poloxamine, monolauric acid POE (20) sorbitan (polysorbate 20), monooleic acid POOE (20) sorbitan (polysorbate 80) P O E sorbitan fatty acid esters such as polysorbate 60, P O E hardened castor oil such as P O E (60) hydrogenated castor oil, P O E alkyl ethers such as P O E (9) lauryl ether, etc. P O E (2 0) P O P (4) P O E .P O P alkyl ethers such as cetyl ether, P O E (1 0) nonyl fe Nonionic surfactants such as P O E alkylphenyl ethers such as nyl ether, P O E alkylphenyl ethers such as P O E (10) nonylphenyl ether, polyoxyl stearate; Glycine such as alkyldiaminoethylglycine Type, amphoteric surfactants such as betaine acetate type such as lauryldimethylaminoacetate betaine; imidazoline type; alkyl ether carboxylates, sulfonates such as sodium tetradecenesulfonate, alkyl sulfates such as sodium lauryl sulfate, N − N-acyl taurine salts such as sodium cocoylmethyl taurate, P O E alkyl ether phosphates such as P O E (10) lauryl ether sodium phosphate and salts thereof, N-acyl amino acids such as sodium lauroylmethylalanine , P O E (3) P O E alkyl ether sulfates such as sodium lauryl ether sulfate, anionic surfactants such as α-olefin sulfonates; alkyl amine salts, alkyls such as benzalkonium chloride, benzethonium chloride Cationic surfactants such as quaternary ammonium salts, alkylpyridinium salts such as cetylpyridinium chloride, cetylpyridinium bromide and the like can be mentioned, and nonionic surfactants are preferred. Furthermore, P O E-P O P block copolymers, P O E sorbitan fatty acid esters, and P O E hardened castor oils are preferred. Among them, poloxamer 407, polysorbate 80, P O E (60) hardened castor oil Is preferable, and polysorbate 80 is particularly preferable.
増粘剤としては、アラビアゴム末、アルギン酸ナトリウム、アルギン酸プロピレングリコールエステル、コンドロイチン硫酸ナトリウム、ソルビトール、デキストラン7 0 、トラガント末、メチルセルロース、カルボキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、カルボキシビニルポリマー、ポリビニルアルコール、ポリビニルピロリドン、マクロゴール4 0 0 0 、ポリオキシエチレンポリオキシプロピレングリコール(ポロクサマー407)、ヒアルロン酸ナトリウム等が挙げられる。 Examples of thickeners include gum arabic powder, sodium alginate, propylene glycol alginate, sodium chondroitin sulfate, sorbitol, dextran 70, tragacanth powder, methylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, carboxyvinyl polymer, polyvinyl alcohol, Examples include polyvinylpyrrolidone, macrogol 4 0 0 0, polyoxyethylene polyoxypropylene glycol (poloxamer 407), sodium hyaluronate, and the like.
キレート剤としては、エデト酸、エデト酸塩類( エデト酸二ナトリウム、エデト酸カルシウム二ナトリウム、エデト酸三ナトリウム、エデト酸四ナトリウム)、ニトリロ三酢酸及びその塩、トリヒドロキシメチルアミノメタン、ヘキサメタリン酸ナトリウム、クエン酸、アスコルビン酸等が挙げられる。 Chelating agents include edetic acid, edetates (disodium edetate, disodium calcium edetate, trisodium edetate, tetrasodium edetate), nitrilotriacetic acid and its salts, trihydroxymethylaminomethane, sodium hexametaphosphate Citric acid, ascorbic acid and the like.
安定化剤としては、前記エデト酸、前記エデト酸塩類、亜硫酸水素ナトリウム、グリセリン、プロピレングリコール、ブドウ糖、マンニトール、ソルビトール等が挙げられる。 Examples of the stabilizer include the edetic acid, the edetates, sodium bisulfite, glycerin, propylene glycol, glucose, mannitol, sorbitol and the like.
防腐剤及び保存剤としては、ソルビン酸、ソルビン酸カリウム、ソルビン酸ナトリウム、パラオキシ安息香酸ブチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸メチル、グルコン酸クロルヘキシジン、塩酸クロルヘキシジン、塩化ベンザルコニウム、塩化ベンゼトニウム、アルキルジアミノエチルグリシン、クロロブタノール、アクリノール、過酸化水素、臭化セチルピリジニウム、ポリドロニウムまたはその塩(例えば、塩化物など)、ビグアニド化合物{ポリヘキサメチレンビグアニドまたはその塩(例えば、塩酸塩など)}等が挙げられる。 Preservatives and preservatives include sorbic acid, potassium sorbate, sodium sorbate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, chlorhexidine gluconate, chlorhexidine hydrochloride, benzalkonium chloride, benzethonium chloride, alkyl Diaminoethylglycine, chlorobutanol, acrinol, hydrogen peroxide, cetylpyridinium bromide, polydronium or its salt (eg, chloride), biguanide compound {polyhexamethylene biguanide or its salt (eg, hydrochloride)} etc. Can be mentioned.
香料としては、各種精油(ウイキョウ油、クールミント油、ケイヒ油、スペアミント油、ハッカ油、ペパーミント油、ベルガモット油、ユーカリ油、ローズ油など)、リモネン、リュウノウ、シネオール、ゲラニオール、オイゲノール等が挙げられる。 Examples of the fragrances include various essential oils (such as fennel oil, cool mint oil, cinnamon oil, spearmint oil, mint oil, peppermint oil, bergamot oil, eucalyptus oil, rose oil), limonene, ryuuno, cineol, geraniol, eugenol, etc. .
用途
本発明の水性組成物は、様々な用途に使用することができるが、高い殺菌力や洗浄力を有しながらも安全性が高いことから、中でも粘膜適用組成物として有用性が高い。粘膜適用組成物の中では、点鼻剤、点耳剤等の耳鼻科用組成物、点眼剤、洗眼剤、コンタクトレンズ用組成物等の眼科用組成物が好ましく、特に眼科用組成物が好ましい。また、眼科用組成物の中でも、本発明の効果がより発揮され得るコンタクトレンズ用組成物が好ましい。コンタクトレンズ用組成物としては、具体的には、コンタクトレンズ装用中に点眼可能な点眼剤(コンタクトレンズ用点眼剤)、コンタクトレンズ装用中に洗眼可能な洗眼剤、コンタクトレンズ装着液、コンタクトレンズケア用組成物が挙げられ、中でもコンタクトレンズケア用組成物が好ましい。また、眼疾患治療用の点眼剤、特にドライアイ用の点眼剤が好ましい。
Applications The aqueous composition of the present invention can be used for various applications, but is highly useful as a composition for applying to mucous membranes because of its high safety while having high bactericidal and detergency. Among the composition applied to mucosa, ophthalmic compositions such as nasal drops and ear drops, ophthalmic compositions such as eye drops, eye washes, and contact lens compositions are preferable, and ophthalmic compositions are particularly preferable. . Among ophthalmic compositions, a composition for contact lenses that can more effectively exert the effects of the present invention is preferable. Specifically, contact lens compositions include eye drops that can be instilled while wearing contact lenses (eye drops for contact lenses), eye wash that can be washed while wearing contact lenses, contact lens mounting solutions, and contact lens care. The composition for contact lenses care is especially preferable. Moreover, eye drops for treating eye diseases, particularly eye drops for dry eye are preferable.
コンタクトレンズケア用組成物としての水性組成物の使用方法としては、例えば、眼から外したコンタクトレンズを容器(レンズケース等)内で該水性組成物と接触させることによって、コンタクトレンズの保存中に増殖する微生物を殺菌あるいは消毒したり、微生物の増殖を抑制しつつコンタクトレンズを保存したり、コンタクトレンズを洗浄することができる。また、本発明の水性組成物は、コンタクトレンズからの汚れ除去力に優れる上、該水性組成物が付着したコンタクトレンズを眼に装着した場合にも安全性が高いため、コンタクトレンズ用すすぎ液としても使用できる。したがって、コンタクトレンズケア用組成物としては、コンタクトレンズ用洗浄液、コンタクトレンズ用消毒液、コンタクトレンズ用殺菌液、コンタクトレンズ用保存液、コンタクトレンズ用すすぎ液などとして有用であり、中でもコンタクトレンズ用洗浄液、コンタクトレンズ用殺菌液、コンタクトレンズ用消毒液が特に好ましい。また、これらのコンタクトレンズケア用組成物の機能のうち、複数の機能を同時に兼ね備えた水性組成物としても使用でき、また殺菌力低下の原因となり得る汚れに対する洗浄効果も高いため、コンタクトレンズケア用の多目的溶液(マルチパーパスソリューション)としても好ましい。また、本願のマルチパーパスソリューションをはじめとするコンタクトレンズケア用組成物は、従来の有機成分の殺菌剤を配合したコールド消毒剤のようにコンタクトレンズに吸着する事なく、また過酸化水素のように中和を必要としないため、非常に安全性及び利便性が高い。 As a method for using the aqueous composition as a contact lens care composition, for example, a contact lens removed from the eye is brought into contact with the aqueous composition in a container (lens case or the like), so that the contact lens can be stored. It is possible to sterilize or disinfect growing microorganisms, store contact lenses while suppressing the growth of microorganisms, and wash contact lenses. In addition, the aqueous composition of the present invention is excellent in the ability to remove dirt from contact lenses, and has high safety even when the contact lens to which the aqueous composition is attached is attached to the eye. Can also be used. Therefore, as a contact lens care composition, it is useful as a contact lens cleaning solution, a contact lens disinfecting solution, a contact lens disinfecting solution, a contact lens storage solution, a contact lens rinsing solution, etc. Contact lens disinfectant and contact lens disinfectant are particularly preferred. Moreover, among these functions of the contact lens care composition, it can be used as an aqueous composition having a plurality of functions at the same time, and also has a high cleaning effect on dirt that can cause a decrease in sterilizing power. It is also preferable as a multipurpose solution (multipurpose solution). In addition, the composition for contact lens care including the multi-purpose solution of the present application does not adsorb to the contact lens like a conventional antiseptic containing a disinfectant of an organic component, and like hydrogen peroxide. Since neutralization is not required, it is very safe and convenient.
マルチパーパスソリューションとしての本発明の使用方法は、具体的には、眼から外したコンタクトレンズに本発明の水性組成物をつけてこすり洗いする工程、該コンタクトレンズを本発明の水性組成物ですすぐ工程、該コンタクトレンズを本発明の水性組成物中に浸漬する工程を含み、本発明の水性組成物から取り出したコンタクトレンズを水や生理食塩液などですすぐことなく、直接に眼に装着することができる。また、本発明の水性組成物は殺菌効果や洗浄効果が極めて優れており、こすり洗いによる微生物や汚れの除去操作を行わなくても十分な効果が得られるため、前述の工程の中で、コンタクトレンズをこすり洗いする工程や、すすぐ工程を省略できる。また、コンタクトレンズを眼から外した後、涙が付着したコンタクトレンズをすすぐ操作を省略する事も可能である。従って、ユーザーにとってのコンタクトレンズ使用時での煩わしさを著しく改善し、また眼障害の発生を予防することができる。 The method of use of the present invention as a multi-purpose solution specifically includes the step of rubbing the contact lens removed from the eye with the aqueous composition of the present invention, and rinsing the contact lens with the aqueous composition of the present invention. A step of immersing the contact lens in the aqueous composition of the present invention, and directly attaching the contact lens taken out of the aqueous composition of the present invention to the eye without rinsing with water or physiological saline. Can do. Further, the aqueous composition of the present invention has an extremely excellent sterilizing effect and cleaning effect, and a sufficient effect can be obtained without performing an operation for removing microorganisms and dirt by rubbing. The process of rubbing the lens and the rinsing process can be omitted. It is also possible to omit the operation of rinsing the contact lens with tears attached after the contact lens is removed from the eye. Therefore, it is possible to remarkably improve the troublesomeness of the user when using contact lenses, and to prevent the occurrence of eye damage.
また、本発明の水性組成物は、眼疾患治療用の点眼剤、特にドライアイ用の点眼剤としても有用性が高い。本発明の亜塩素酸類化合物を含有する水性組成物を含む点眼剤は、塩化ベンザルコニウム、グルコン酸クロルヘキシジン、メチルパラベンなどの界面活性作用のある防腐剤を含有せず、また涙液中のタンパク質などの汚染物質の共存下でも製剤中の亜塩素酸類化合物の殺菌力が低下しないことから、ドライアイ等に使用できる。 The aqueous composition of the present invention is also highly useful as an eye drop for treating eye diseases, particularly as an eye drop for dry eye. The eye drop comprising the aqueous composition containing the chlorite compound of the present invention does not contain a preservative having a surfactant activity such as benzalkonium chloride, chlorhexidine gluconate, methylparaben, and proteins in tears Since the bactericidal activity of chlorite compounds in the preparation does not decrease even in the presence of other pollutants, it can be used for dry eye and the like.
以下に実施例を挙げて本発明を具体的に説明するが、これらの実施例は何ら本発明の範囲を限定するものではない。なお、特に断らない限り、以下の表中、各成分の量は配合量であり、また特に単位の記載のないものについては、すべてw/v%を表す。また、全ての試験例において用いる亜塩素酸ナトリウムは、各表で示される濃度となるように、「シルブライト25FD(日本カーリット(株)製)」を用いて配合した。 EXAMPLES The present invention will be specifically described below with reference to examples, but these examples do not limit the scope of the present invention. In addition, unless otherwise indicated, in the following table | surfaces, the quantity of each component is a compounding quantity, Moreover, especially the thing without the description of a unit represents w / v%. Moreover, the sodium chlorite used in all the test examples was blended using “Sylbright 25FD (manufactured by Nippon Carlit Co., Ltd.)” so as to have a concentration shown in each table.
試験例1 殺菌力試験1
表1に示す組成の水性組成物(実施例1及び比較例1、2)を配合調製し、これらを用いて殺菌力試験を実施した。
具体的には、カンジダ・アルビカンス(Candida albicans: ATCC 10231)及びスタフィロコッカス・アウレウス(Staphylococcus aureus: ATCC 6538)を、ソイビーン・カゼイン・ダイジェスト(SCD)寒天平板培地の表面に接種して、33℃で24時間培養を行った。培養菌体を白金耳で無菌的に採取し、適量の滅菌生理食塩液に浮遊させて、約1×108コロニー形成単位(CFU)/mLの生菌を含む細菌浮遊液を調製した。この細菌浮遊液に対して、各水性組成物を適量添加して、表1に示す初期菌濃度にした後に23℃で静置した。各水性組成物について、保存8時間後の1mL当たりの生菌数を測定した。
Test Example 1 Bactericidal power test 1
Aqueous compositions (Example 1 and Comparative Examples 1 and 2) having the compositions shown in Table 1 were blended and prepared, and a bactericidal test was conducted using them.
Specifically, Candida albicans (ATCC 10231) and Staphylococcus aureus (ATCC 6538) were inoculated on the surface of a soybean casein digest (SCD) agar plate medium at 33 ° C. For 24 hours. The cultured cells were aseptically collected with a platinum loop and suspended in an appropriate amount of sterile physiological saline to prepare a bacterial suspension containing about 1 × 10 8 colony forming units (CFU) / mL viable bacteria. An appropriate amount of each aqueous composition was added to the bacterial suspension to obtain the initial bacterial concentration shown in Table 1, and then allowed to stand at 23 ° C. For each aqueous composition, the number of viable bacteria per mL after 8 hours of storage was measured.
結果を表1に併せて示す。この結果から、比較例1及び2の水性組成物のいずれにおいても殺菌力が不十分であったのに対して、実施例1の水性組成物は、カンジダ・アルビカンス及びスタフィロコッカス・アウレウスに対して優れた殺菌力を示すことが明らかとなった。この実施例1の水性組成物の殺菌力は、各比較例1−2の試験結果から表される各配合成分の殺菌力をはるかに凌いだ、優れた効果であることは明らかである。また、本試験例で使用した菌種はスタンドアロン試験で通常使用される菌種であることから、本発明の水性組成物は涙液等で汚染されたコンタクトレンズをはじめとしたコンタクトレンズ用殺菌液として優れた効果を有することは明らかである。
試験例2 殺菌力試験2
表2に示す組成の水性組成物(実施例2及び比較例3、4)を配合調製し、これらを用いて以下の方法により殺菌力試験を実施した。
具体的には、スタフィロコッカス・アウレウス(Staphylococcus aureus: ATCC 6538)を、ソイビーン・カゼイン・ダイジェスト(SCD)寒天平板培地の表面に接種して、33℃で24時間培養を行った。培養菌体を白金耳で無菌的に採取し、適量の滅菌生理食塩水に浮遊させて、約1×108コロニー形成単位(CFU)/mLの生菌を含む細菌浮遊液を調製した。
また、2mLのタンパク液(卵白リゾチーム 0.12%、牛血清アルブミン 0.388%、牛γグロブリン 0.161%、豚胃ムチン 0.1%、CaCl2・2H2O 0.015%、NaCl 0.9%、NaH2PO4・2H2O 0.045%、0.1N NaOHでpH 7.0調整)に、予め大塚生理食塩水に一晩浸漬しておいたコンタクトレンズ(2ウィークアキュビュー、ジョンソンアンドジョンソン社製)を24時間振とう(34℃、120rpm条件下)させることにより、タンパク汚れ付着レンズを作製した。
さらに、ゾーンクイック(昭和薬品化工(株)製)にて4名の両眼から2本づつ涙液を採取した。計16本のゾーンクイックを大塚生理食塩水500μLで抽出し、0.2μmステラディスク(クラボウ製)で濾過滅菌した液を涙液抽出液とした。
15mL容量滅菌済PETチューブに試験液を3mL分注した。そこに、上記タンパク汚れ付着レンズ一枚及び上記涙液抽出液30μLを加えた後、細菌浮遊液を添加し、表2に示す初期菌濃度にした後に23℃で静置した。保存4時間後の各水性組成物について、1mL当たりの生菌数を測定した。
Test Example 2 Bactericidal power test 2
Aqueous compositions (Example 2 and Comparative Examples 3 and 4) having the compositions shown in Table 2 were blended and prepared, and a bactericidal test was conducted by the following method.
Specifically, Staphylococcus aureus (ATCC 6538) was inoculated on the surface of a soy bean casein digest (SCD) agar plate and cultured at 33 ° C. for 24 hours. The cultured cells were aseptically collected with a platinum loop and suspended in an appropriate amount of sterile physiological saline to prepare a bacterial suspension containing about 1 × 10 8 colony forming units (CFU) / mL of live bacteria.
2 mL protein solution (egg white lysozyme 0.12%, bovine serum albumin 0.388%, bovine gamma globulin 0.161%, porcine stomach mucin 0.1%, CaCl 2 · 2H 2 O 0.015%, NaCl 0.9%, NaH 2 PO 4 · 2H 2 O 0.045%, the pH 7.0 adjusted) in 0.1 N NaOH, contact lens (2 Week Acuvue which had been soaked overnight in advance Otsuka physiological saline , Johnson & Johnson) was shaken for 24 hours (34 ° C., 120 rpm) to prepare a protein soiled lens.
Furthermore, two tear fluids were collected from both eyes of four persons using Zonequick (manufactured by Showa Yakuhin Kako Co., Ltd.). A total of 16 zone quicks were extracted with 500 μL of Otsuka physiological saline and filtered and sterilized with a 0.2 μm Stella disk (manufactured by Kurabo Industries) as a tear extract.
3 mL of the test solution was dispensed into a 15 mL sterilized PET tube. Then, after adding one protein soil adhering lens and 30 μL of the tear extract, a bacterial suspension was added to obtain the initial bacterial concentration shown in Table 2 and allowed to stand at 23 ° C. The number of viable bacteria per mL was measured for each aqueous composition after 4 hours of storage.
結果を表2に示す。この結果から、比較例3−4の水性組成物のいずれにおいても殺菌力が不十分であったのに対して、実施例2の水性組成物はスタフィロコッカス・アウレウスに対して、タンパクや涙液由来の汚れが混入した場合においても優れた殺菌力を示すことが明らかとなった。この実施例2の水性組成物の殺菌力は、各比較例の試験結果から表される各配合成分の殺菌力をはるかに凌いだ優れた効果であることは明らかである。
以上の結果より、本発明の水性組成物は、亜塩素酸類化合物の単独またはl−メントールなどの成分の単独についての殺菌力効果と比較して、当業者の予測を超えた、際立って優れた効果を示した。 From the above results, the aqueous composition of the present invention is remarkably superior to those skilled in the art as compared with the bactericidal effect of the chlorite compound alone or the component alone such as l-menthol. Showed the effect.
製剤例
下記の表に示す処方に従い、常法により、本発明の製剤を調製した。なお表中の製剤実施例は例示であって、これらに限定されない。なお、実施例3から8で表される水性組成物はコンタクトレンズ用多目的溶液(マルチパーパスソリューション)、コンタクレンズ用洗浄液、コンタクトレンズ用すすぎ液、コンタクトレンズ用消毒液またはコンタクトレンズ用保存液として使用できる。また、実施例9から16で表される水性組成物は、点眼剤、洗眼剤またはコンタクトレンズ用点眼剤として使用できる。
本発明の水性組成物は、メントール、メントン、カンフルおよびボルネオールからなる群から選択される少なくとも1種の成分を配合することにより、亜塩素酸類化合物の殺菌力や洗浄力が著しく増強された、亜塩素酸類化合物の配合組成物である。また本発明の組成物は、特にコンタクトレンズ用組成物として有用であり、中でもコンタクトレンズケア用組成物としては、コンタクトレンズをこすることなく高い殺菌効果や洗浄効果を得られる為、物理的破損の恐れも低く有用である。本発明の水性組成物は、塩化ベンザルコニウム、グルコン酸クロルヘキシジン、メチルパラベンなどの界面活性作用のある防腐剤を含有せず、また涙液中のタンパク質などの汚染物質の共存下でも亜塩素酸類化合物の殺菌力が低下しない為、眼疾患治療用の点眼剤、特にドライアイ用の点眼剤としても有用である。従って、本発明の水性組成物は、コンタクトレンズ用組成物をはじめとする眼科用組成物やその他の粘膜適用組成物として期待でき、工業的利用価値が高い。 The aqueous composition of the present invention has a sublimation and detergency of chlorite compounds that are remarkably enhanced by blending at least one component selected from the group consisting of menthol, menthone, camphor and borneol. It is a blended composition of chloric acid compounds. The composition of the present invention is particularly useful as a composition for contact lenses, and among them, as a composition for contact lens care, a high bactericidal effect and cleaning effect can be obtained without rubbing the contact lens, so that physical damage It is useful with low fear. The aqueous composition of the present invention does not contain a preservative having a surfactant activity such as benzalkonium chloride, chlorhexidine gluconate, methylparaben, and chlorite compounds even in the presence of contaminants such as proteins in tears Therefore, it is useful as an eye drop for treating eye diseases, particularly as an eye drop for dry eye. Therefore, the aqueous composition of the present invention can be expected as an ophthalmic composition including a composition for contact lenses and other mucosa-applied compositions, and has high industrial utility value.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013223062A JP2014028857A (en) | 2008-02-07 | 2013-10-28 | Chlorous acid compound-containing aqueous composition containing menthol |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008027584 | 2008-02-07 | ||
JP2008027584 | 2008-02-07 | ||
JP2013223062A JP2014028857A (en) | 2008-02-07 | 2013-10-28 | Chlorous acid compound-containing aqueous composition containing menthol |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009025705A Division JP5401113B2 (en) | 2008-02-07 | 2009-02-06 | Aqueous composition containing chlorous acid compounds containing menthols |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2014028857A true JP2014028857A (en) | 2014-02-13 |
Family
ID=41182644
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009025705A Active JP5401113B2 (en) | 2008-02-07 | 2009-02-06 | Aqueous composition containing chlorous acid compounds containing menthols |
JP2013223062A Pending JP2014028857A (en) | 2008-02-07 | 2013-10-28 | Chlorous acid compound-containing aqueous composition containing menthol |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009025705A Active JP5401113B2 (en) | 2008-02-07 | 2009-02-06 | Aqueous composition containing chlorous acid compounds containing menthols |
Country Status (1)
Country | Link |
---|---|
JP (2) | JP5401113B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018067895A1 (en) * | 2016-10-06 | 2018-04-12 | Ora, Inc. | Screening agents in dry eye disease |
JP2021522264A (en) * | 2018-04-27 | 2021-08-30 | アラーガン、インコーポレイテッドAllergan,Incorporated | Sodium chlorite composition with enhanced antimicrobial efficacy and reduced toxicity |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012005311A1 (en) * | 2010-07-06 | 2012-01-12 | ロート製薬株式会社 | Composition for contact lens care |
EP2653155A4 (en) * | 2010-12-17 | 2014-06-04 | Rohto Pharma | Ophthalmic composition for contact lens |
TWI607768B (en) * | 2017-03-31 | 2017-12-11 | 晶碩光學股份有限公司 | Composition for contact lenses and method for caring contact lenses |
JP2019101120A (en) * | 2017-11-29 | 2019-06-24 | 日油株式会社 | Solution for contact lens |
EP4473837A1 (en) * | 2022-03-31 | 2024-12-11 | Earth Corporation | Composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002219162A (en) * | 2000-11-16 | 2002-08-06 | Senju Pharmaceut Co Ltd | Unheated disinfectant for soft contact lens |
JP2003279906A (en) * | 2003-03-17 | 2003-10-02 | Rohto Pharmaceut Co Ltd | Eye drop containing refrigerant and used for contact lens |
WO2005025539A1 (en) * | 2003-09-10 | 2005-03-24 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition for contact lens |
JP2007045819A (en) * | 2005-07-13 | 2007-02-22 | Santen Pharmaceut Co Ltd | Preservative composition for ophthalmic use |
JP2007269807A (en) * | 2007-05-31 | 2007-10-18 | Rohto Pharmaceut Co Ltd | Eye drop for contact lens wearers, containing refrigerative agent |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753334A (en) * | 1993-08-13 | 1995-02-28 | Monamuule:Kk | Hair restoring and growing cosmetic |
JP5064114B2 (en) * | 2000-12-28 | 2012-10-31 | ロート製薬株式会社 | Ophthalmic composition |
JP4248172B2 (en) * | 2000-12-28 | 2009-04-02 | ロート製薬株式会社 | Soft contact lens care products |
JP5041761B2 (en) * | 2005-08-10 | 2012-10-03 | ロート製薬株式会社 | Ocular mucosa application |
EP2039370A4 (en) * | 2006-06-16 | 2013-05-22 | Rohto Pharma | Ophthalmic composition for soft contact lens comprising terpenoid |
-
2009
- 2009-02-06 JP JP2009025705A patent/JP5401113B2/en active Active
-
2013
- 2013-10-28 JP JP2013223062A patent/JP2014028857A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002219162A (en) * | 2000-11-16 | 2002-08-06 | Senju Pharmaceut Co Ltd | Unheated disinfectant for soft contact lens |
JP2003279906A (en) * | 2003-03-17 | 2003-10-02 | Rohto Pharmaceut Co Ltd | Eye drop containing refrigerant and used for contact lens |
WO2005025539A1 (en) * | 2003-09-10 | 2005-03-24 | Senju Pharmaceutical Co., Ltd. | Ophthalmic composition for contact lens |
JP2007045819A (en) * | 2005-07-13 | 2007-02-22 | Santen Pharmaceut Co Ltd | Preservative composition for ophthalmic use |
JP2007269807A (en) * | 2007-05-31 | 2007-10-18 | Rohto Pharmaceut Co Ltd | Eye drop for contact lens wearers, containing refrigerative agent |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018067895A1 (en) * | 2016-10-06 | 2018-04-12 | Ora, Inc. | Screening agents in dry eye disease |
JP2021522264A (en) * | 2018-04-27 | 2021-08-30 | アラーガン、インコーポレイテッドAllergan,Incorporated | Sodium chlorite composition with enhanced antimicrobial efficacy and reduced toxicity |
US11738043B2 (en) | 2018-04-27 | 2023-08-29 | Allergan, Inc. | Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity |
JP7490570B2 (en) | 2018-04-27 | 2024-05-27 | アラーガン、インコーポレイテッド | Sodium chlorite compositions having enhanced antimicrobial effectiveness and reduced toxicity |
Also Published As
Publication number | Publication date |
---|---|
JP5401113B2 (en) | 2014-01-29 |
JP2009209140A (en) | 2009-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2374607T3 (en) | Ophthalmic compositions with an amphoteric surfactant and hyaluronic acid. | |
JP2014028857A (en) | Chlorous acid compound-containing aqueous composition containing menthol | |
JP2005523261A (en) | Ophthalmic composition containing oil-in-water emulsion and method for producing and using the same | |
JP5877795B2 (en) | Contact lens ophthalmic composition | |
AU2003210699A1 (en) | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same | |
CN101151038A (en) | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye | |
JP2006505501A (en) | Ophthalmic, pharmaceutical and other health care preparations with naturally occurring plant compounds, extracts and derivatives | |
JP2022001579A (en) | Eye drops for nonionic silicone hydrogel contact lenses | |
JP5700479B2 (en) | Eye drops for silicone hydrogel contact lenses | |
JPH09278610A (en) | Composition for controlling harmful microorganism | |
JP5686454B1 (en) | Contact lens mounting liquid and method for improving refractive index of contact lens using the same | |
JP2009199074A (en) | Aqueous composition containing chlorous acid compound containing polyoxyethylene castor oil derivative and phosphoric acid compound | |
JP4981181B1 (en) | Contact lens composition | |
KR101726029B1 (en) | Ophthalmic compositions with alkoxylated natural waxes | |
JP2009175731A (en) | Chlorous acids compound-containing water-based composition containing glycerol and phosphoric acid compound | |
JP5927045B2 (en) | Ophthalmic aqueous composition | |
JP5587359B2 (en) | Contact lens composition | |
JP6983009B2 (en) | Ophthalmic composition | |
KR101605145B1 (en) | Contact lenses solution for removing microorganism and acanthamoebae | |
JP2023009258A (en) | Ophthalmological preparation | |
JP4817621B2 (en) | Contact lens care method and composition | |
JP2006000170A (en) | Contact lens composition | |
JP4533110B2 (en) | Ophthalmic solution | |
JP4524538B2 (en) | Ophthalmic composition | |
EP2262521B1 (en) | Ophthalmic compositions comprising a dipeptide with a glycine moiety |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140902 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150224 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150630 |